secwatch.observer — SEC 8-K summary
======================================

Issuer:     EKSO BIONICS HOLDINGS, INC. (CHRN)
CIK:        0001549084
Form:       8-K/A
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0001549084-23-000004
Event type: m_and_a
Sentiment:  negative
Materiality: 0.70
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ekso Bionics acquires Parker Hannifin's HMC business for $10M; HMC had $2.2M op loss in FY2022
--------------------------------------------------------------------------------

- Acquisition closed Dec 5, 2022; purchase price $10M: $5M cash + $5M subordinated zero-coupon note due Sep 2027.
- HMC FY2022 (Jun 2022) revenue $4.3M, operating loss $2.2M; FY2021 loss $4.0M on $2.7M revenue.
- Pro forma 9mo Sep 2022 combined net loss $14.8M ($1.14 diluted EPS) vs Ekso standalone $11.9M loss.
- Preliminary purchase price allocation: $5.2M intangible assets, $0.7M goodwill, $1.0M property step-ups.
- HMC unaudited 3mo Sep 2022 revenue $390k, operating loss $1.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549084/000154908423000004/0001549084-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549084/000154908423000004/ekso-20221205.htm
  HTML page:      https://secwatch.observer/filing/0001549084-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer